Press Releases PRNewswire

‫شركة CHiQ تحوز على الجوائز الدولية لقوة علامتها التجارية

تشونغشان، الصين، 12 يناير 2023 /بي آر نيوزواير/ — تم مؤخرًا تصنيف تشانغهونغ، أكبر شركة مصنعة للأجهزة الكهربائية المنزلية الصينية وعلامتها التجارية المتميزة تشيك ( CHiQ) ، كواحدة من أفضل 10 علامات تجارية عالمية للتلفزيونات في عام 2022-2023. تعد أفضل العلامات التجارية العالمية حدثًا عالميًا يعبر عن الثقة والاحترافية والمصداقية – قاعة الشرف في مجال الإلكترونيات الاستهلاكية […]

Press Releases PRNewswire

Hisense Enriches Home Entertainment Options for South African Consumers with Launch of New U80H Mini-LED ULED 8K TV

CAPE TOWN, South Africa, Jan. 12, 2023 /PRNewswire/ — Leading global electronics brand, Hisense, has recently announced the launch of the U80H Mini-LED ULED 8K TV in South Africa. The U80H TV delivers never-before-seen depth and detail, with 33 million pixels – 4 times more than a standard 4K TV. The next-generation smart TV also […]

Press Releases PRNewswire

Hisense Enriches Home Entertainment Options for South African Consumers with Launch of New U80H Mini-LED ULED 8K TV

CAPE TOWN, South Africa, Jan. 12, 2023 /PRNewswire/ — Leading global electronics brand, Hisense, has recently announced the launch of the U80H Mini-LED ULED 8K TV in South Africa. The U80H TV delivers never-before-seen depth and detail, with 33 million pixels – 4 times more than a standard 4K TV. The next-generation smart TV also […]

GLOBE-NEWSWIRE Press Releases

Zenas BioPharma administra a primeira dose em paciente, dando início à Fase 3 do Estudo Clínico do Obexelimab para o tratamento de doença relacionada à imunoglobulina G4 (IgG4-RD)

O estudo Global de Fase 3 INDIGO avaliará a eficácia e a segurança do obexelimab em pacientes com IgG4-RD, uma doença fibroinflamatória crônica e grave que normalmente afeta múltiplos órgãos A IgG4-RD é a primeira de várias indicações potenciais de doença a serem testadas com o obexelimab, dada sua inibição única de células B não […]

GLOBE-NEWSWIRE Press Releases

Zenas BioPharma administra a primeira dose em paciente, dando início à Fase 3 do Estudo Clínico do Obexelimab para o tratamento de doença relacionada à imunoglobulina G4 (IgG4-RD)

O estudo Global de Fase 3 INDIGO avaliará a eficácia e a segurança do obexelimab em pacientes com IgG4-RD, uma doença fibroinflamatória crônica e grave que normalmente afeta múltiplos órgãos A IgG4-RD é a primeira de várias indicações potenciais de doença a serem testadas com o obexelimab, dada sua inibição única de células B não […]